GGrantIndex
Sort

40,608 grants matching prostate cancer

MINORITY BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM

$459,263
Mobile Infirmary Medical Center · U10 · FY2003 · CA

Tumor Immunology & Host Response

$459,262
Max S. Wicha · University Of Michigan At Ann Arbor · P30 · FY2013 · CA

Lectin Resistant Tumor Cells and Functional Glycomics

$459,250
Pamela M Stanley · Albert Einstein College Of Medicine · R01 · FY2019 · GM

Lectin Resistant Tumor Cells and Functional Glycomics

$459,250
Pamela M Stanley · Albert Einstein College Of Medicine · R01 · FY2020 · GM

SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT) FOR PROSTATE CANCER

$459,204
E David Crawford · University Of Colorado Denver · M01 · FY2006 · RR

The role of Phosphoinositide 3 Kinase isoforms in Prostate Cancer

$459,197
Lewis C Cantley · Beth Israel Deaconess Medical Center · P01 · FY2007 · CA

Whole Genome Association Study of Mammographic Density

$459,193
Rulla M Tamimi · Brigham And Women'S Hospital · R01 · FY2009 · CA

NOVEL OPTICAL METHODS FOR IDENTIFICATION, IMAGING, PRESERVATION OF CAVERNOUS NERVES RESPONSIBLE FOR PENILE ERECTIONS DURING PROSTATE CANCER SURGERY

$459,158
University Of North Carolina At Charlotte · · FY2008 · Department of Defense

Serum Antibody Profiling with a Carbohydrate Microarray

$459,103
Jeff Gildersleeve · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA

Stress Induction of Glucose Regulated Protein GRP78/BiP

$459,080
Amy S Lee · University Of Southern California · R01 · FY2012 · CA

Genomic Imprinting in Cancer

$459,042
Andrew P Feinberg · Johns Hopkins University · R01 · FY2007 · CA

Probe Optimization for Prostate Cancer Detection

$459,037
Clifford Berkman · Washington State University · R01 · FY2012 · CA

IMPACT OF MARYLAND'S ALL-PAYER MODEL ON RACIAL AND SOCIOECONOMIC DISPARITIES IN PROSTATE CANCER MANAGEMENT

$458,955
New York University · · FY2025 · Defense Health Agency

Biomarkers for Prostate and Bladder Cancer

$458,951
University Of Washington · U01 · FY2005 · CA

Developing clinical, immunologic and radiographic tools to measure the clinical effect of immunotherapy in biochemically recurrent prostate cancer

$458,934
Philip W Kantoff · Sloan-Kettering Inst Can Research · U01 · FY2017 · CA

HOMING PEPTIDES FOR THE VASCULATURE IN PROSTATE

$458,895
Erkki I Ruoslahti · Sidney Kimmel Cancer Center · P01 · FY2007 · CA

Development of assays for HTS to identify inhibitors of a new PPI involved in cancer metastasis

$458,880
Celine Dermardirossian · San Diego Biomedical Research Institute · R01 · FY2018 · CA

Geisinger Clinical Oncology Program

$458,852
Albert Michael Bernath · Geisinger Medical Center · U10 · FY2007 · CA

PSMA-VRP vaccine for prostate cancer

$458,795
William C Olson · Progenics Pharmaceuticals, Inc. · R44 · FY2007 · CA

Proteomics Biomarkers Development Laboratory

$458,633
Samir M Hanash · Fred Hutchinson Cancer Research Center · U01 · FY2008 · CA

Molecular Recognition of Proteins and Ligand Design

$458,593
William Jorgensen · Yale University · R01 · FY2020 · GM

Canine models for characterization, diagnosis, and treatment of human cancers using comparative canine-human transcriptomics

$458,591
Gregory Tawa · National Center For Advancing Translational Sciences · ZIA · FY2018 · TR

Cancer Immunotherapy Clinical Trials

$458,587
Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Real time fine needle assessment of architectural heterogeneity in prostate cancer

$458,577
Guan Xu · University Of Michigan At Ann Arbor · R37 · FY2021 · CA

Human Leukemia Growth Inhibition by a Novel Retinoid

$458,562
Joseph A Fontana · Wayne State University · R01 · FY2007 · CA